MedPath

An observational, multicentre, prospective study to see concordance of detecting EGFR mutation by circulating tumour free DNA versus tissues biopsy in Non small cell lung cancer

Not Applicable
Completed
Conditions
Health Condition 1: C342- Malignant neoplasm of middle lobe,bronchus or lungHealth Condition 2: null- Non-small cell lung cancer
Registration Number
CTRI/2018/08/015290
Lead Sponsor
AstraZeneca Pharma India Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
245
Inclusion Criteria

1. Patients who provide written informed consent

2. Patients aged 18 years and older

3. Newly diagnosed patients with Metastatic (stage IV) NSCLC.

4. Histologically confirmed Adenocarcinoma NSCLC patients as per tissue biopsy and the sample sent for EGFR mutation analysis.

5. Patient should be naïve for any systemic treatment (i.e. no chemotherapy or EGFR-TKI)

6. Provision of a routine blood (plasma) sample

The prescription of any medicinal product is clearly separated from the decision to include the subject in the study.

Exclusion Criteria

1. Patient with any medical condition that, in the opinion of the investigator, would interfere with outcome of the study

2. Patient participating in any other interventional clinical study/trial.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Determine the level of concordance between EGFR mutation status obtained by tissue and blood (plasma) based testing in terms of Overall Concordance, Sensitivity specificity Positive predictive value and negative predictive valueTimepoint: one day
Secondary Outcome Measures
NameTimeMethod
1. Determine the frequency of mutations on Exon 19,20 & 21 of EGFR gene (including mutation subtypes: exon 19 deletions and the L858R) among study patients as assessed by the plasma samples <br/ ><br>2. Assess the frequency of T790M mutation among study patientsTimepoint: one day
© Copyright 2025. All Rights Reserved by MedPath